Across TCGA pan-cancer cohorts, MIR520D Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR520D data layer compared with 4 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MIR520D Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR520D expression acts as an unfavorable survival marker.
OV are the cancer types where MIR520D Mutation most reproducibly stratifies survival.